A new case of platelet-type von Willebrand disease supports the recent findings of gain-of-function GP1BA variants outside the C-terminal disulphide loop enhances affinity for von Willebrand factor.


Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
11 2023
Historique:
revised: 23 07 2023
received: 28 04 2023
accepted: 24 07 2023
medline: 15 11 2023
pubmed: 18 8 2023
entrez: 18 8 2023
Statut: ppublish

Résumé

Platelet-type von Willebrand disease (PT-VWD) is a rare autosomal dominant bleeding disorder characterized by an increased ristocetin-induced platelet aggregation (RIPA) and enhanced affinity of platelet glycoprotein Ibα (GPIbα) to von Willebrand factor (VWF). To date, only seven variants have been described with this gain-of-function effect, most of them located in the C-terminal disulphide loop of the VWF-binding domain of GPIbα. We herein describe a patient with moderate bleeding symptoms, mild thrombocytopenia and increased RIPA. By direct sequencing of GP1BA, a novel leucine-rich repeat heterozygous variant was identified (c.580C>T; predictably p.Leu194Phe), strongly suggestive as being the underlying cause for the PT-VWD phenotype of our patient.

Identifiants

pubmed: 37592722
doi: 10.1111/bjh.19025
doi:

Substances chimiques

von Willebrand Factor 0
Platelet Glycoprotein GPIb-IX Complex 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

673-677

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Références

Tischer A, Machha VR, Moon-Tasson L, Auton M. Platelet-type von Willebrand disease: local disorder of the platelet GPIbα β-switch drives high-affinity binding to von Willebrand factor. J Thromb Haemost. 2019;17(12):2022-2034.
Othman M, Lopez JA, Ware J. Platelet-type von Willebrand disease update: the disease, the molecule and the animal model. Expert Rev Hematol. 2011;4(5):475-477.
Othman M, Gresele P. Guidance on the diagnosis and management of platelet-type von Willebrand disease: a communication from the Platelet Physiology Subcommittee of the ISTH. J Thromb Haemost. 2020;18(8):1855-1858.
Bury L, Falcinelli E, Bhotla HK, Mezzasoma AM, Guglielmini G, Tischer A, et al. A p.Arg127Gln variant in GPIba LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD. Blood Adv. 2022;6(7):2236-2246.
Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost. 2011;37(5):464-469.
Luo SZ, Mo X, Afshar-Kharghan V, Srinivasan S, López JA, Li R. Glycoprotein Ibα forms disulfide bonds with 2 glycoprotein Ibβ subunits in the resting platelet. Blood. 2007;109(2):603-609.
Othman M. Platelet-type Von Willebrand disease: three decades in the life of a rare bleeding disorder. Blood Rev. 2011;25(4):147-153. https://doi.org/10.1016/j.blre.2011.03.003
Favaloro EJ, Patterson D, Denholm A, Mead S, Gilbert A, Collins A, et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol. 2007;139(4):621-628.
Bury L, Malara A, Momi S, Petito E, Balduini A, Gresele P. Mechanisms of thrombocytopenia in platelet-type von Willebrand disease. Haematologica. 2019;104(7):1473-1481.
Woods AI, Sanchez-Luceros A, Bermejo E, Paiva J, Alberto MF, Grosso SH, et al. Identification of pW246L As a novel mutation in the GP1BA gene responsible for platelet-type von Willebrand disease. Semin Thromb Hemost. 2014;40(2):151-160.
Miller JL, Cunningham D, Lyle VA, Finch CN, Pincus MR. Mutations in the gene encoding the alpha chain of platelet glycoprotein IB. Biotechnol Adv. 1997;15(3-4):680-681.
Russell SD, Roth GJ. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ibα gene associated with a hyperactive surface receptor. Blood. 1993;81(7):1787-1791.
Matsubara Y, Murata M, Sugita K, Ikeda Y. Identification of a novel point mutation in platelet glycoprotein Ibα, Gly to ser at residue 233, in a Japanese family with platelet-type von Willebrand disease. J Thromb Haemost. 2003;1(10):2198-2205.
Othman M, Notley C, Lavender FL, White H, Byrne CD, Lillicrap D, et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood. 2005;105(11):4330-4336.
Enayat MS, Guilliatt AM, Lester W, Wilde JT, Williams MD, Hill FGH. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance. Br J Haematol. 2006;133(6):664-666.
Li R, Emsley J. The organizing principle of the platelet glycoprotein Ib-IX-V complex. J Thromb Haemost. 2013;11(4):605-614.
Morais S, Oliveira J, Lau C, Pereira M, Gonçalves M, Monteiro C, et al. αIIbβ3 variants in ten families with autosomal dominant macrothrombocytopenia: expanding the mutational and clinical spectrum. PLoS One. 2020;15(12):235136.

Auteurs

Catarina Monteiro (C)

Laboratório de Genética Molecular, Centro de Genética Médica Jacinto Magalhães, Centro Hospitalar Universitário de Santo António (CHUdSA), Porto, Portugal.
Unidade de Trombose e Hemostase & Centro de Coagulopatias Congénitas, Serviço de Imuno-hemoterapia, CHUdSA, Porto, Portugal.
UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and Biomedical Sciences, University of Porto (UMIB/ICBAS/UP), Porto, Portugal.
ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal.

Ana Gonçalves (A)

Laboratório de Genética Molecular, Centro de Genética Médica Jacinto Magalhães, Centro Hospitalar Universitário de Santo António (CHUdSA), Porto, Portugal.
UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and Biomedical Sciences, University of Porto (UMIB/ICBAS/UP), Porto, Portugal.
ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal.

Mónica Pereira (M)

Unidade de Trombose e Hemostase & Centro de Coagulopatias Congénitas, Serviço de Imuno-hemoterapia, CHUdSA, Porto, Portugal.
UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and Biomedical Sciences, University of Porto (UMIB/ICBAS/UP), Porto, Portugal.
ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal.

Catarina Lau (C)

UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and Biomedical Sciences, University of Porto (UMIB/ICBAS/UP), Porto, Portugal.
ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal.
Unidade de Diagnóstico Hematológico Margarida Lima, Serviço de Imuno-hemoterapia, CHUdSA, Porto, Portugal.

Sara Morais (S)

Unidade de Trombose e Hemostase & Centro de Coagulopatias Congénitas, Serviço de Imuno-hemoterapia, CHUdSA, Porto, Portugal.
UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and Biomedical Sciences, University of Porto (UMIB/ICBAS/UP), Porto, Portugal.
ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal.

Rosário Santos (R)

Laboratório de Genética Molecular, Centro de Genética Médica Jacinto Magalhães, Centro Hospitalar Universitário de Santo António (CHUdSA), Porto, Portugal.
UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and Biomedical Sciences, University of Porto (UMIB/ICBAS/UP), Porto, Portugal.
ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH